10 July 2020 - BEAM Alliance

BEAM Alliance – Reflection paper on the EU Pharmaceutical Strategy Roadmap

BEAM welcome the European Commission's ambition to support innovation in its upcoming Pharmaceutical Strategy. In our latest paper , we…

27 August 2020 - BEAM Alliance

BEAM Alliance – Reflection paper on the AMR Action Fund

The COVID-19 pandemic has stressed how drug and vaccine development requires time and resources. Whilst we welcome the launch of…

28 August 2020 - BEAM Alliance

BEAM Alliance and global partners call for urgent action on new reimbursement models for life-saving antibiotics

18 November 2020 - BEAM Alliance

2020 Antimicrobial Resistance campaign: How to change the fight against AMR?

The BEAM Alliance recently worked with Global Cause on the 2020 Antimicrobial Resistance campaign.

22 January 2021 - BEAM Alliance

BEAM Alliance Joined The One Health Good Practices For The Successful Management Of Antimicrobial Resistance

The BEAM Alliance decided to join the Call To Action of the AMR Stakeholder Network, supported by the European Public…

BEAM News
Member News
Events

Latest news of BEAM Alliance

22 January 2021 - BEAM Alliance

BEAM Alliance Joined The One Health Good Practices For The Successful Management Of Antimicrobial Resistance

The BEAM Alliance decided to join the Call To Action of the AMR Stakeholder Network, supported by the European Public…

18 November 2020 - BEAM Alliance

2020 Antimicrobial Resistance campaign: How to change the fight against AMR?

The BEAM Alliance recently worked with Global Cause on the 2020 Antimicrobial Resistance campaign.

09 November 2020 - BEAM Alliance

Antibiorésistance : Anticiper une nouvelle crise sanitaire

Florence Séjourné, présidente de BEAM Alliance : « Il faut anticiper les investissements en R&D dès maintenant pour avoir un…

28 August 2020 - BEAM Alliance

BEAM Alliance and global partners call for urgent action on new reimbursement models for life-saving antibiotics

27 August 2020 - BEAM Alliance

BEAM Alliance – Reflection paper on the AMR Action Fund

The COVID-19 pandemic has stressed how drug and vaccine development requires time and resources. Whilst we welcome the launch of…

10 July 2020 - BEAM Alliance

BEAM Alliance – Reflection paper on the EU Pharmaceutical Strategy Roadmap

BEAM welcome the European Commission's ambition to support innovation in its upcoming Pharmaceutical Strategy. In our latest paper , we…

page 1/4

Tweets by alliancebeam

View twitter feed

Latest news of BEAM Members

12 July 2021 - Aptorum Group Ltd

Aptorum Group Announces Further Positive Interim Results of the Phase 1 Clinical Trial of ALS-4 Targeting Staphylococcus aureus

As part of Aptorum Group’s Acticule infectious disease platform, ALS-4 is a novel first-in-class orally administered small molecule drug based…

24 June 2021 - VetoPhage

Pour lutter contre l’antibiorésistance, la startup française Vetophage révolutionne l’approche de la détection et des traitements des bactéries pathogènes chez les animaux grâce aux phages

Chatain-Ly Mai Huong, fondatrice et présidente de Vetophage, souligne : « Nous sommes dorénavant en présence de bactéries résistantes à…

21 June 2021 - NovaBiotics Ltd

NovaBiotics Announces Cysteamine Bitartrate (NM002) Included in REMAP-CAP Phase 3 Clinical Trial for Community Acquired Pneumonia

“This study can provide real-world clinical evidence in a range of CAPs potentially in thousands of patients across several continents.…

01 June 2021 - NovaBiotics Ltd

NovaBiotics Announces Publication of Data Elucidating NP339’s Broad Antifungal Activity in Antimicrobial Agents and Chemotherapy

Deborah O’Neil, PhD, OBE, FRSE, Chief Executive Officer of NovaBiotics, commented: “Development of antifungals with no off-target pharmacology is challenging…

01 June 2021 - BioVersys AG

BioVersys receives a second CARB-X award of up to US$ 15.34 million for BV300

The pyrrolocytosines (BV300) represent a novel chemical class of small molecules inhibiting the bacterial ribosome, a validated antibacterial target, but…

25 May 2021 - Nabriva Therapeutics GmbH

Sinovant Sciences and Nabriva Therapeutics Announce Positive Topline Results from Phase 3 Trial of Lefamulin in Chinese Adults with Community Acquired Bacterial Pneumonia (CABP)

Lefamulin (marketed by Nabriva in the United States as XENLETA®) is a first-in-class, semi-synthetic pleuromutilin antibiotic for systemic administration in…

page 1/30

Events

17 November 2021

6th Annual Microbiome Connect: Gut Therapeutics

This event is a unique gathering of individuals from academia and industry who are collaborating to advance microbiome science.

16 October 2021

5th International Course on Antibiotics and Resistance (ICARe)

The emergence and spread of bacteria resistant to many drug classes seriously threaten all branches of modern medicine. There is…

20 September 2021

BioPharm America™ Digital

BioPharm America™ Digital creates a robust exchange among executives from major pharmaceutical companies, biotechnology companies of every size and stage,…

24 August 2021

5th AMR Conference – Summer Edition

The AMR conference is the one-stop-shop for all AMR stakeholders from industry, SMEs, start-ups, big pharma, academia, clinics, regulatory bodies,…

27 July 2021

REVIVE Webinar: Discovering and developing new treatments for fungal infections

REVIVE is a space for everybody with an interest in antimicrobial R&D. The Global Antibiotic Research and Development Partnership (GARDP)…

01 July 2021

REVIVE Webinar: Balancing access to and stewardship of antimicrobials in LMICs

REVIVE is a space for everybody with an interest in antimicrobial R&D. The Global Antibiotic Research and Development Partnership (GARDP)…

24 June 2021

Promoting Innovative Antibiotic R&D in Switzerland – Online Event

The event "Promoting Innovative Antibiotic R&D in Switzerland” brings together protagonists of Antibiotic Research and Development from academic, industrial, political…

10 June 2021

REVIVE Webinar: Openly accessible resources for the global antimicrobial R&D community

REVIVE is a space for everybody with an interest in antimicrobial R&D. The Global Antibiotic Research and Development Partnership (GARDP)…

27 May 2021

Free Webinar: Revisiting and Rebuilding Clinical Development of Drugs for Antimicrobial Resistance – Lessons Learned During the COVID Pandemic

In this webinar, we bring together AMR experts to discuss how we can use the momentum from the pandemic to…

page 1/10